Emerging approaches, such as combining the PARP inhibitor niraparib with the anti–PD-L1 agent durvalumab (NCT04538378), are under investigation for SCLC-transformed EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.